These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

99 related items for PubMed ID: 7533361

  • 1. Whole-blood and plasma levels of FK 506 after liver transplantation: results from the US Multicenter Trial. FK506 Multicenter Study Group.
    Bäckman L, Levy MF, Klintmalm G.
    Transplant Proc; 1995 Feb; 27(1):1124. PubMed ID: 7533361
    [No Abstract] [Full Text] [Related]

  • 2. FK 506 in liver transplantation: correlation of whole blood levels with efficacy and toxicity. The US Multicenter FK 506 Dose Optimization.
    Schwartz M, Holst B, Facklam D, Buell D.
    Transplant Proc; 1995 Feb; 27(1):1107. PubMed ID: 7533355
    [No Abstract] [Full Text] [Related]

  • 3. Comparing nephrotoxicity of FK 506 and cyclosporine regimens after liver transplantation: preliminary results from US Multicenter trial. U.S. Multicenter Liver Study Group.
    Porayko MK, Gonwa TA, Klintmalm GB, Wiesner RH.
    Transplant Proc; 1995 Feb; 27(1):1114-6. PubMed ID: 7533358
    [No Abstract] [Full Text] [Related]

  • 4. Plasma level-guided low-dose FK 506 therapy in patients with early liver dysfunction after liver transplantation.
    Winkler M, Ringe B, Jost U, Gubernatis G, Pichlmayr R.
    Transplant Proc; 1993 Aug; 25(4):2688-90. PubMed ID: 7689277
    [No Abstract] [Full Text] [Related]

  • 5. Hyperlipidemia after liver transplantation: long-term results of the FK506/cyclosporine A US Multicenter Trial. US Multicenter Study Group.
    Abouljoud MS, Levy MF, Klintmalm GB.
    Transplant Proc; 1995 Feb; 27(1):1121-3. PubMed ID: 7533360
    [No Abstract] [Full Text] [Related]

  • 6. Prognostic factors for successful conversion from cyclosporine to FK 506-based immunosuppressive therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group.
    Klintmalm GB, Goldstein R, Gonwa T, Wiesner RH, Krom RA, Shaw BW, Stratta R, Ascher NL, Roberts JW, Lake J.
    Transplant Proc; 1993 Feb; 25(1 Pt 1):641-3. PubMed ID: 7679828
    [No Abstract] [Full Text] [Related]

  • 7. Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group.
    Klintmalm GB, Goldstein R, Gonwa T, Wiesner RH, Krom RA, Shaw BW, Stratta R, Ascher NL, Roberts JW, Lake J.
    Transplant Proc; 1993 Feb; 25(1 Pt 1):679-88. PubMed ID: 7679840
    [Abstract] [Full Text] [Related]

  • 8. Weight gain and lipid profile changes in liver transplant recipients: long-term results of the American FK506 Multicenter Study.
    Mor E, Facklam D, Hasse J, Sheiner P, Emre S, Schwartz M, Miller C.
    Transplant Proc; 1995 Feb; 27(1):1126. PubMed ID: 7533363
    [No Abstract] [Full Text] [Related]

  • 9. Use of FK 506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. US Multicenter FK 506 Liver Study Group.
    Klintmalm GB, Goldstein R, Gonwa T, Wiesner RH, Krom RA, Shaw BW, Stratta R, Ascher NL, Roberts JW, Lake J.
    Transplant Proc; 1993 Feb; 25(1 Pt 1):635-7. PubMed ID: 7679826
    [No Abstract] [Full Text] [Related]

  • 10. FK 506 rescue therapy for resistant rejection episodes in liver transplant recipients.
    D'Alessandro AM, Kalayoglu M, Pirsch JD, Corwith C, Knechtle SJ, Reed A, Belzer FO.
    Transplant Proc; 1991 Dec; 23(6):2987-8. PubMed ID: 1721335
    [No Abstract] [Full Text] [Related]

  • 11. Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients.
    Jain AB, Fung JJ, Tzakis AG, Venkataramanan R, Abu-Elmagd K, Alessiani M, Reyes J, Irish W, Warty V, Mehta S.
    Transplant Proc; 1991 Dec; 23(6):2763-6. PubMed ID: 1721270
    [No Abstract] [Full Text] [Related]

  • 12. Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled, prospective, randomized trial.
    Jonas S, Kling N, Bechstein WO, Blumhardt G, Lohmann R, Lobeck H, Neuhaus P.
    Clin Transplant; 1995 Oct; 9(5):406-14. PubMed ID: 8541635
    [Abstract] [Full Text] [Related]

  • 13. Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group.
    Bismuth H.
    Transplant Proc; 1995 Feb; 27(1):45-9. PubMed ID: 7533415
    [No Abstract] [Full Text] [Related]

  • 14. FK 506 treatment of intractable rejection after liver transplantation.
    Jost U, Winkler M, Ringe B, Rodeck B, Pichlmayr R.
    Transplant Proc; 1993 Aug; 25(4):2686-7. PubMed ID: 7689276
    [No Abstract] [Full Text] [Related]

  • 15. Whole blood and plasma levels of FK 506 after liver transplantation: correlation with toxicity.
    Bäckman L, Nicar M, Levy M, Distant D, Eisenstein C, Renard T, Goldstein R, Husberg B, Gonwa T, Klintmalm G.
    Transplant Proc; 1994 Jun; 26(3):1804. PubMed ID: 7518160
    [No Abstract] [Full Text] [Related]

  • 16. Early experience with FK 506 induction immunosuppression--suggestion for using oral FK 506.
    Nakazato P, Cox K, Concepcion W, Gish R, Berquist W, Imperial J, Esquivel C.
    Transplant Proc; 1991 Dec; 23(6):3019-20. PubMed ID: 1721345
    [No Abstract] [Full Text] [Related]

  • 17. Clinical use of FK 506 in liver transplantation.
    Klintmalm GB.
    Transplant Proc; 1996 Apr; 28(2):974-6. PubMed ID: 8623484
    [Abstract] [Full Text] [Related]

  • 18. Effect of hematocrit on pharmacokinetics of tacrolimus in adult living donor liver transplant recipients.
    Minematsu T, Sugiyama E, Kusama M, Hori S, Yamada Y, Ohtani H, Sawada Y, Sato H, Takayama T, Sugawara Y, Makuuchi M, Iga T.
    Transplant Proc; 2004 Jun; 36(5):1506-11. PubMed ID: 15251372
    [Abstract] [Full Text] [Related]

  • 19. Similar clinical presentation of neurotoxicity following FK 506 and cyclosporine in a liver transplant recipient.
    Freise CE, Rowley H, Lake J, Hebert M, Ascher NL, Roberts JP.
    Transplant Proc; 1991 Dec; 23(6):3173-4. PubMed ID: 1721397
    [No Abstract] [Full Text] [Related]

  • 20. Successful reconversion from tacrolimus to cyclosporine A Neoral in pediatric liver recipients.
    Melter M, Rodeck B, Kardorff R, Hoyer PF, Maibücher A, Brodehl J.
    Transplant Proc; 1996 Aug; 28(4):2276-8. PubMed ID: 8769224
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.